Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received the second year of funding under its U.S. Food and Drug Administration (FDA) Office of Orphan Products Development …
Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial Read More